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ABSTRACT 
WILLIAM GUST: The Pharmacodynamic Functions of Low-Dose Rapamycin as a 
Model for Universal Influenza Protection 
(Under the Direction of Dr. John M. Rimoldi) 
 
 One of the most sought after breakthroughs in modern influenza research is the 
creation of a universal influenza vaccine that would protect against all strains of avian 
influenza. An unlikely model for this kind of protection might be found in the mTOR 
inhibitor rapamycin. Traditionally used to prevent organ transplant rejection, low doses 
of rapamycin have been found to protect mice against infection with distinct subtypes of 
influenza. However, it is not understood how a partial block in this pathway provides 
optimal heterosubtypic immunity. Interestingly, previous experiments have shown that 
low dose rapamycin inhibits germinal center formation to reduce antibody class 
switching and generate cross-protective influenza antibodies. Yet, it is not known how 
these antibodies, which do not neutralize the virus, enhance protection against distinct 
influenza subtypes. 
  The focus of my research was to further characterize the antibody protection and 
mTORC1 downstream effector regulation mediated by low dose rapamycin. Significant 
mechanisms of viral clearance by non-neutralizing antibodies include complement-
mediated phagocytosis and antibody-dependent cell-mediated cytotoxicity (ADCC). To 
investigate whether these mechanisms are required for rapamycin-mediated antibody 
protection in vivo, we inhibited the complement system in vivo using Cobra Venom 
Factor (CVF), depleted natural killer cells in vivo using an anti-NK1.1 antibody, and 
compared the efficacy of rapamycin treatment between control and depleted mice 
following H5N1 infection in both cases. We also performed an in vitro ADCC assay with 
serum from PBS or rapamycin-treated mice. Based on our data, we concluded that 
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rapamycin-mediated antibodies do not use the complement system or ADCC to provide 
heterosubtypic influenza protection.   
To understand how low-dose rapamycin specifically alters the expression of 
certain downstream mTOR effectors, we ran quantitative Polymerase Chain Reaction 
(qPCR) analyses on RNA isolated from PBS and rapamycin-treated B cells. Additionally, 
we ran western blots on PBS and rapamycin-treated B cells to investigate how low-dose 
rapamycin uses phosphoregulation to alter downstream mTORC1 protein expression. 
Based on our data, we found that rapamycin decreases expression of the Slc2a1 gene, 
which encodes Glucose transporter 1 (GLUT1), and the phosphoprotein pS6, which helps 
encode B cell ribosome biogenesis. In addition, rapamycin may alter the expression of 
other genes, but to a lesser extent.  
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CHAPTER 1 
INTRODUCTION 
1.1: HISTORY OF INFLUENZA 
The term “influenza” was born in 14th Century Italy as an explanation for the 
cause of disease, described by a variety of ailments whose appearances were believed to 
be dictated by the position, or influence, of the stars1. Though it is now accepted that the 
virus’s history began much earlier and had little to do with the cosmos, unanimity 
regarding its exact origin remains elusive. One camp of medical historians believes that 
the first record of a true influenza epidemic resides in Book VI of Hippocrates’ On 
Epidemics series2. Book VI describes a pestilence with symptoms commonly attributed to 
the influenza virus, such as fatigue, coughing, and fever, that swept the northern Greek 
port town of Perinthus in 412 B.C3. Proponents argue that these symptoms, and the 
correspondence of the outbreak with the winter solstice, provide strong evidence that 
Perinthus was plagued by influenza virus2. Others dispute that the book’s marked 
inconsistencies with modern knowledge of influenza—namely, the presence of other 
symptoms not related to influenza, and the absence of pneumonia in relapse cases—cast 
sufficient doubt on the disease’s identity4. Doubt also arises from the inherent potential 
for error from the secondhand authorship of the account. Unlike Books I, III, and V, 
which were written by the man himself, Books II, IV, VI, and VII were written by 
Hippocrates’ son Thessalus using his father’s notes as a guide5. Thus, others posit that the 
first likely influenza event came in the form of an epidemic that decimated French King 
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Charlemagne’s army in 876 A.D. during his attempted conquest of Europe6. Still 
others only consider accounts written during or after the Middle Ages as reliable 
representations of true influenza events6. While many arguments exist, lack of hard data 
and sufficient corroboration have ensured that the search for influenza’s origin remains 
speculative for the time being. 
By the 16th Century, influenza had already earned a page in the history books with 
a series of devastating epidemics that altered the course of numerous wars and devastated 
entire countries at a time. However, the year 1510 marked the first recognized influenza 
pandemic6,7. Starting in Asia and quickly spreading to Africa and Europe, the pandemic 
demonstrated the true spreading potential of the influenza virus7. The next flu pandemic 
in 1557 further raised the stakes with significantly higher mortality rates than the 1510 
pandemic6. The final pandemic of the 16th Century occurred during 1580, and spread over 
contiguous Eurasia, Africa, and possibly the Americas to kill 8,000 Roman citizens, 
entire Spanish towns, and countless others8. Almost as alarming as the death toll of the 
1580 pandemic was the quickness with which it spread. Unlike the 1557 pandemic, 
whose death toll was spread out over the next few years, the 1580 pandemic killed all of 
its victims within the span of one year6,9. After a brief lull in the 17th Century, influenza 
pandemics would rise again and continue to sporadically arise, infect, and kill over the 
next two centuries. With the exception of a few outliers, the number of infected 
individuals remained within certain parameters, and the number of casualties rarely 
eclipsed a million. All this soon changed in the 20th Century with the arrival of an 
especially virulent strain that would mark the next turning point in the history of 
influenza.  
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Coming on the heels of the First World War, the infamous influenza pandemic of 
1918 infected a third of the world’s population and killed anywhere from 50-100 million 
people in what still stands as the deadliest single event in all of human history6,10. The 
colloquially-named Spanish Flu achieved this enormous level of destruction over the 
course of three successive infection waves that all occurred within a single year’s time. 
The first and mildest of these waves was by most measures unremarkable; though its 
morbidity rates were somewhat high, its mortality rates fell well within the parameters of 
previous pandemics, giving no reason to fear any worse10. A few months later, the second 
wave of infection arrived without warning. Emerging first in southern England, the 
nightmarish outburst killed millions of victims and set new precedent for the lethal 
potential of an influenza pandemic10-11. Almost as astonishing as how many people it 
killed was whom it killed, and whom it didn’t. Bucking the tradition of previous 
influenza pandemics that had primarily affected the oldest and youngest individuals, the 
second wave of the Spanish Flu plucked most of its victims from the least likely 
population: young adults between 20 and 40 years of age9. Although elderly and infant 
populations did experience relatively higher mortality rates than the general population 
during the second wave, young children and adults over 65 were surprisingly spared12. 
These trends gave rise to what became known as the W-shaped mortality curve, formed 
from mortality rate peaks in newborns, young adults, and the elderly12. The third and 
final wave of the 1918 pandemic was the only one to appear during influenza’s usual 
winter season10. While milder than its bloodthirsty predecessors, the last chapter of the 
Spanish Flu still managed to cause thousands of deaths, both in previously hit countries 
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such as Spain, and in new countries such as Australia13. Fortunately, like its brethren 
before it, the last outburst subsided within a few months10.  
As the 1918 pandemic wound down to a close, the world was left ravaged and 
confused by the worst medical catastrophe it had ever known. Much remained unclear. 
Despite the recognition of influenza as the causative agent and extensive research efforts 
during the pandemic, scientists were still stumped as to what influenza actually was, and 
how it had caused so much destruction. The generally accepted theory at the time alleged 
that a bacterium known as Bacillus influenzae, which had previously been isolated from 
the nostrils of influenza victims, was the perpetrator behind the disease14. In spite of some 
conflicting evidence for this theory, the search for additional answers largely died down 
with the pandemic. Thus, another decade would pass before the true source was 
identified.  
The first step to catching the deadliest serial killer of all time was taken 
unintentionally by Rockefeller Institute researcher Richard E. Shope in 1931. Shope and 
his mentor Paul Lewis were investigating a disease outbreak in Iowan pigs, which was 
dubbed “swine influenza” for its striking similarities to the human pestilence15. Expecting 
to find a bacterial cause of morbidity, the pair were surprised to discover that isolated 
bacterium alone did not induce disease16. Further experiments revealed that the real 
culprit behind initial infection was small enough to pass through a bacteria-resistant filter 
and caused mild infections on its own17. When combined with the isolated bacterium, 
however, the tiny perpetrator was found to induce the same serious condition initially 
seen in the affected pigs17. Therefore, Shope declared that severe swine influenza was the 
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result of a coinfection, a principle that would redefine the understanding of influenza 
pandemics.  
Two years after Shope’s invigorating discoveries, human influenza virus was 
isolated by Wilson Smith, Christopher Andrewes, and Patrick Laidlaw18. Using Shope’s 
technique, the three scientists filtered throat samples from influenza patients of the 1933 
epidemic through bacterially-impermeable material. The trio inoculated an initial cohort 
of ferrets with the filtrates after discovering their susceptibility to sickness through trial 
and error. After the first ferrets demonstrated obvious influenza symptoms with infection, 
their nostrils were scraped and emulsified for injection into other ferrets. In this way, 26 
ferrets were infected with the same influenza virus, each from scrapings of the previous 
ferret. Even with potential dilution from multiple sample transfers, each ferret in the 
series still succumbed to the effects of the original filtrate. To prove the filtrate’s 
infectious agent could not be a bacterium, the team stimulated the filtrates with a variety 
of bacterial cultures and growth factors. Not a single bacterium grew, and the scientists 
concluded, once and for all, that the source of influenza had to be a virus18.  
The published findings of Shope, Smith, Andrewes, and Laidlaw inspired many 
upcoming scientists to pursue careers in the exciting new fields of virology and influenza 
research15. The resultant boom in these fields yielded fifteen years of discovery that 
yielded a much enhanced characterization of the virus, and the development of its first 
vaccine11. Yet for all these advancements, man still lacks the proper tools to prevent and 
sequester influenza pandemics. The first evidence of this deficiency came in the form of 
the H2N2 influenza pandemic of 1957-58. Originating in China, the so-called Asian flu 
spread across the globe in a matter of 4 months6. Although vaccines were developed, 
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distribution delays and low efficacy prevented them from being a significant factors in 
the containment of H2N211,19. Even with this setback, and two distinct waves of 
infectious attack, the mortality rate of the 1957 pandemic was comparatively mild to its 
1918 predecessor. It is estimated that over the course of the entire pandemic, less than 2 
million people were killed by the Asian strain9,20. The next exhibition of influenza’s 
tenacity, the 1968 H3N2 pandemic, was similarly mild. Spread by air travel and Vietnam 
War veterans, the Hong Kong Flu infected people in two successive waves, killing about 
2 million people11,21. The rapid spread and high mortality rates of the Asian and Hong 
Kong influenza strains demonstrated that, despite vaccine development, man was no 
closer to preventing influenza pandemics than he had been in 1918.  
Named for its porcine genetic origin, the most recent and mildest influenza 
pandemic was the 2009 Swine Flu. In spite of shared protein subtypes with the Spanish 
Flu, and a similar disproportionate attack on those under 65 years of age, the 2009 H1N1 
pandemic only caused an estimated 575,400 deaths globally22. It is not known whether 
the reduced death toll of this pandemic was due to human ingenuity, or viral 
characteristics. Some facts are evident, however. Even though the 2009 pandemic had a 
reduced death toll, humanity once again failed to prevent another pandemic with modern 
viral combative tools. Thus, if another pandemic were to arrive tomorrow, man would 
still be unable to prevent it.  
 
1.2 CHARACTERIZATION OF THE INFLUENZA VIRUS  
 All influenza viruses belong to the Orthomyxoviridae family of antisense ssRNA 
viruses23. From the shared Orthomyxoviridae family, influenza viruses diverge into 
7 
 
influenza types A, B, C, and D based on their host range and overall severity. Although 
types A, B, and C infect humans, only types A and B are capable of causing severe 
disease and epidemics, and only type A is capable of causing pandemics24. Thus, only 
influenza types A and B are of clinical significance, and have vaccines developed against 
them. Each type acquires a protective lipid envelope during intracellular assembly that is 
derived from the lipid bilayer of the host cell23,25. This borrowed bilayer houses three 
surface proteins of significance: the glycoproteins hemagglutinin (HA) and 
neuraminidase (NA), and the Matrix-2 (M2) proton channel26. Of these three proteins, 
HA and NA are the most clinically significant due to their key pathogenic functions and 
overall prevalence on the viral surface. HA constitutes 80% of the viral surface proteins, 
and promotes cellular infection by coordinating the attachment to and penetrance of a 
host cell27. NA makes up 17% of viral surface proteins, and promotes infection spread by 
coordinating cellular exit27. Thus, HA and NA subtypes define an influenza strain, and 
are the primary antigenic targets of the immune system’s antibody response.  
Due to pressure from the immune response, recurrence of influenza requires 
mutations in HA and NA sufficient to evade immunological memory. Most of these 
mutations arise from errors during viral RNA replication. Unlike DNA, RNA cannot 
repair its own mutational errors, so these changes accumulate over time28. Those strains 
that accumulate enough mutations to evade the immune response are able to spread 
efficiently, which is known as antigenic drift.  
Although mutated viruses gain new antigenic glycoprotein subtypes, some 
segments of the original glycoprotein structure are often conserved. When exposed to a 
virus with a certain set of conserved glycoprotein segments, the immune system will 
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develop a degree of cross-protection against all viruses with those segments. Since 
antibodies are generated against these structures, antibodies previously generated against 
a certain glycoprotein structure may exhibit some affinity for glycoproteins on other 
influenza viruses with similar structures. Thus, conserved glycoprotein segments can 
mediate the induction of a limited secondary immune response, which leads to cross-
protection against similar mutated influenza viruses. While this cross-protection alone is 
not enough to prevent an influenza infection, it can reduce its overall severity. The 
conferrable pathogenicity of glycoprotein mutation is thusly limited. With this 
mechanism as its sole method of adaptation, influenza B viruses are incapable of 
becoming highly pathogenic pandemic viruses. For this reason, and the greater 
prevalence of human influenza A viruses, the majority of vaccines are designed to protect 
against influenza A strains.   
The spread of highly pathogenic influenza A strains, such as the H5N1 and H7N9, 
in birds, poses a new threat for a pandemic. Most viruses from this avian reservoir cannot 
efficiently infect humans due to differences in host cell binding sites: the HA of avian 
viruses binds sialic acids with α (2, 3) galactose linkages, while the HA of human viruses 
binds sialic acids with α (2, 6) galactose linkages27. However, mutations in the avian 
viruses can enable them to bind to α (2, 6) galactose linkages. In addition, multiple 
viruses can simultaneously infect an animal and mix their genes to make completely 
novel viruses28. These rare events, known as an antigenic shifts, result in the creation of 
new, highly pathogenic viruses that can cause global infections due to lack of previous 
immunity in the human population29. Thus, it is access to the avian reservoir that confers 
influenza A viruses with pandemic potential. Although the H5N1 and H7N9 avian strains 
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do not transmit efficiently between humans, several human infections with these viruses 
have been confirmed. Of these confirmed infections, 40% of those infected with H7N9 
and 60% with H5N1 have died30-31. Thus, if these viruses mutated so that they could 
transmit efficiently between humans and maintained their high mortality rate, millions of 
people would die.  
 
1.3: MODALITY AND LIMITATION OF THE SEASONAL INFLUENZA 
VACCINE 
 The most effective defense against influenza infections is vaccination32. Current 
vaccines prevent infection by stimulating the production of specific, neutralizing 
antibodies against the HA and NA glycoproteins of preselected viral strains. These 
antibodies bind to the HA and prevent the virus from binding receptors on the host 
epithelial cells, or bind the NA and prevent the spread of the virus from one cell to 
another. Neutralizing antibodies are produced following vaccination after viral antigens 
are processed and transported to the lymph nodes by antigen-presenting cells (APCs), 
namely dendritic cells and macrophages33,34. In the lymph nodes, APCs activate B cells 
and T cells by displaying these antigens to specific receptors on each cell. Activated B 
cells internalize, modify, and display the antigen via MHC II (Major Histocompatibility 
Complex) receptors, which in turn activate T cells34. Upon meeting and binding, 
activated B and T cells form structures in the lymph nodes known as germinal centers 
(GCs). In the GC, antibodies that bind to the antigen with the highest affinity are selected 
to develop through a process known as somatic hypermutation. In addition, in the GC, 
antibodies undergo class switch recombination and switch from the IgM to the IgG 
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isotype, which allows the antibodies to acquire specific functions34. These processes 
heighten the specificity of B cell antibodies against vaccine glycoprotein antigens 
through modification of variable and constant antibody regions33,35. Following the GC 
reaction, the B cells proliferate extensively. Although most activated B cells become 
antibody-secreting plasma cells, some B cells differentiate into memory B cells to initiate 
a quick immune response should the virus be encountered again. It is the production of 
these memory cells with specific, neutralizing antibodies that confers protection against 
infection with the influenza strains represented by the vaccine.  
 Unfortunately, the seasonal influenza vaccine is not without its weaknesses. 
Perhaps the most glaring of its insufficiencies is its inevitable obsolescence. Due to the 
constant antigenic drift of the virus, the vaccine of the previous influenza season will 
become outdated by the next one, if not long before. Thus, the vaccine must be updated 
each season to reflect whichever strains researchers predict to be most prevalent at the 
start of production36. This flaw in itself would not be so egregious if it were not for the 
length of time required to produce the vaccine. As it stands, the most common method of 
mass production involves growing the virus in fertilized hen’s eggs37. While the viral egg 
growth only takes three weeks, the necessary optimization, purification, regulation, and 
testing extends the total production time to about five or six months at best38. The large 
gap between identification of strains and distribution of vaccines gives the virus more 
time to mutate and potentially outpace the vaccine. In this way, the current method of 
production diminishes both specific influenza vaccine efficacy and general influenza 
vaccine faith.  
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 A host of other factors further reduce the vaccine’s protective ability by limiting 
its general efficacy. Vaccine effectiveness varies with both demographic and viral 
characteristics. In human populations, vaccine efficacy is affected by age and health. 
Young, healthy people generally have stronger immune systems and typically respond 
better to vaccines than the elderly or individuals with chronic disease36. The viral subtype 
also impacts vaccine effectiveness. A meta-analysis conducted from 2004-2015 found the 
effectiveness for each vaccine subtype to be as follows: 33% for H3N2 viruses; 54% for 
Influenza B viruses; and 61% for H1N1 viruses39. With data from independent studies 
such as this one and its own internal research, the CDC estimates that, at best, the vaccine 
can only reduce the risk of contracting influenza infection by 50-60% on average36.  
 More disconcerting than its shortcomings in the fight against seasonal influenza 
infections is this the current vaccine’s inherent inability to provide proper protection in 
the event of a pandemic. Most influenza pandemics have run to completion within the 
span of a single year6. Many of these, including the especially lethal pandemic of 1918, 
have incurred the majority of their morbidity and mortality in merely two to three months 
over a single wave of infection10. At the current pace of mass production, a viable 
vaccine would not be ready in time to prevent or treat such a strain, leaving the global 
population essentially defenseless against it. Assuming the vaccine was produced in time 
to confer some benefit, it would likely only come to the developed world, while limits in 
distribution would likely leave the developing world high and dry until the pandemic had 
already passed40. The best case scenario in such an event would be a continuation of the 
trend established in the last three pandemics: widespread morbidity, relatively low 
mortality, and inevitable economic disruption from mass sickness. Yet there is no 
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guarantee that this pattern will persist. Should a novel viral strain arise from the avian 
reservoir, humanity must be ready, or suffer incalculable consequences.  
 It should be noted that while the influenza vaccine is the most effective treatment 
option against influenza infection, it is not the only one available. Active treatments also 
exist in the form of antiviral medications. Although these drugs can reduce the duration 
of an influenza infection by one to two days, which can make a large difference in 
patients with certain disorders, they are not sufficient to cure or prevent infection41. 
Furthermore, influenza antivirals do not work against all strains; since their mechanism 
of action is based on NA inhibition, mutations or recombinations in NA can inhibit 
antiviral therapy42. Thus, influenza antivirals are not a viable solution in the event of a 
pandemic virus, and are only mildly effective against seasonal epidemic viruses.  
 
1.4: RAPAMYCIN: A POTENTIAL MODEL FOR A UNIVERSAL INFLUENZA 
VACCINE 
 Despite available therapies, influenza causes 250,000-500,000 deaths per year43. 
Given this, and our practical defenselessness against highly pathogenic and potentially 
lethal pandemic influenza viruses with current treatments, it is evident that a new remedy 
will be necessary to conquer influenza. The most pursued path to influenza eradication in 
recent years has been the search for a universal influenza vaccine. Theoretically, a 
universal vaccine would provide immunity against all subtypes of influenza—a concept 
known as heterosubtypic immunity—by producing neutralizing antibodies against 
epitopes conserved in all subtypes of influenza, including highly pathogenic pandemic 
strains. Although antibodies cross-reactive against all HA subtypes have been discovered 
13 
 
in humans, these antibodies are extremely rare and insufficient production of 
corresponding memory cells prevents their establishment of heterosubtypic immunity44–
46. Thus, an effective universal influenza vaccine will require strong stimulation of both 
conserved cross-reactive antibodies and sufficient corresponding memory cells.  
 In 2013, our lab discovered that mice treated with a low dose of the 
immunosuppressant, rapamycin, during influenza vaccination, had increased levels of 
cross-reactive influenza antibodies47. Consequently, rapamycin-treated mice were 
protected against subsequent infections with multiple subtypes of influenza. Traditionally 
used at higher doses as a prophylactic to prevent renal transplant rejection, rapamycin 
suppresses the immune system by inhibiting a regulatory serine/threonine kinase known 
as mTOR48,49. mTOR mediates cell survival, metabolism, and proliferation in response to 
extracellular stimuli such as nutrients, growth factors, and antigen50,51. Surprisingly, 
Araki et al. found that treatment of mice with a low dose of rapamycin (75 µg/kg) 
actually boosted production of memory CD8+ cytotoxic T cells52. Since CD8+ T cells 
dominate the immune response to the internal, conserved influenza proteins, we tested 
whether rapamycin could enhance heterosubtypic immunity in a mouse model53,54. Mice 
were infected intraperitoneally with an H3N2 influenza virus (HKx31). Because 
influenza does not replicate outside of the respiratory tract, infection via this route allows 
the virus to produce the full spectrum of proteins without an infection, and therefore 
serves as a model of vaccination.  After 28 days, mice were challenged by an intranasal 
infection with a H5N1 strain (Vn1203). In addition, one group of mice was treated daily 
with 75 µg/kg of rapamycin beginning one day prior to vaccination and ending the day 
before the challenge.  In mice treated with a Phosphate-Buffered Saline (PBS) control, 
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vaccination with H3N2 did provide some protection, however 70% of the mice died 
following the H5N1 infection. In contrast, less than 10% of the mice treated daily with 
rapamycin died following the H5N1 infection, indicating that rapamycin significantly 
increases heterosubtypic immunity to influenza virus47. Through further investigation, it 
was discovered that rapamycin enhanced survival by altering the antibody response 
during the vaccination. Rapamycin diminished germinal center formation to effectively 
reduce antibody class switching. As a result, rapamycin-treated mice had higher levels of 
influenza-specific IgM antibodies, as well as antibodies with distinct specificities than 
control-treated mice. We use rapamycin treatment as a model to understand what 
parameters of the immune response confer optimal heterosubtypic immunity. 
 
1.5: AIMS AND OBJECTIVES 
Although it is known that rapamycin inhibits mTOR, it is not understood how a 
partial block in this pathway provides optimal heterosubtypic immunity. Furthermore, it 
is not clear which pathways downstream of mTOR are blocked with the low dose of 
rapamycin used in our model. Additionally, we do not understand how the antibodies 
generated in the presence of rapamycin enhance protection against distinct subtypes.  
  The first aim of my project was to investigate how antibodies generated in the 
presence of rapamycin provide heterosubtypic immunity. We specifically investigated 
whether these antibodies required the use of the complement system or antibody-
dependent cell-mediated cytotoxicity (ADCC) to provide such protection. To test the role 
of complement, we inhibited the complement system in vivo using Cobra Venom Factor 
(CVF), and compared the efficacy of rapamycin treatment between control and CVF-
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treated mice following H5N1 infection. To examine ADCC, we depleted natural killer 
(NK) cells, which mediate ADCC, and tested whether rapamycin treatment enhances 
heterosubtypic immunity in their absence. We also performed an in vitro ADCC assay 
with serum from PBS or rapamycin-treated mice. Based on our data, we concluded that 
rapamycin-mediated antibodies do not use the complement system or ADCC to provide 
heterosubtypic influenza protection.   
The second aim of my project was to understand how low-dose rapamycin 
specifically alters the expression of certain downstream mTOR effectors. To this end, we 
ran quantitative Polymerase Chain Reaction (qPCR) analyses on RNA isolated from PBS 
and rapamycin-treated B cells. Based on our data, we found that rapamycin decreases 
expression of the Slc2a1 gene, which encodes Glucose transporter 1 (GLUT1). In 
addition, rapamycin may alter the expression of other genes, but to a lesser extent.   
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CHAPTER 2 
MATERIALS AND METHODS 
2.0: GENERAL in vivo TREATMENT MODEL  
Mice 
Female 8-10 week old C57 BL/6J mice were purchased from the Jackson Laboratory and 
held under specific pathogen-free conditions at St. Jude Children’s Research Hospital. 
All in vivo experiments used this breed of mice unless otherwise noted.  
 
Low-Dose Rapamycin Treatment Protocol 
 
All in vivo experiments were planned using the following treatment template: On 
Day -1, mice receive their first assigned treatment of either 0.1 mL Phosphate-Buffered 
Saline (PBS), or low-dose rapamycin (Rap)—defined here as a concentration of 75 µg/kg 
of body weight diluted in PBS—via intraperitoneal injection (i.p.). On Day 0, mice are 
infected i.p. with of 1 x 108 egg 50% infective dose (EID50) of HKx31 virus, which
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contains 6 internal genes of A/Puerto Rico/8/34 (PR8) and H3 and N2 glycoproteins. This 
virus undergoes a defective growth cycle in which all viral proteins are produced without 
infectious virus to mimic a vaccine-like effect. Following 28 more days of assigned 
treatment, mice are challenged with an intranasal (i.n.) infection of 4.5 x 105 EID50 of 
A/Vietnam/1203/04 virus, a lethal dose. This H5N1 virus contains the internal PR8 
genes, and was modified for use in a BSL2 facility. Survival and weight loss data are then 
recorded over the next 10-12 days.  
 
2.1: CVF EXPERIMENT 
 
Infection and Observation 
A cohort of 40 mice was divided equally into four treatment groups: PBS 
(Phosphate-Buffered Saline), PBS + CVF, Rap, and Rap + CVF. PBS and Rap treatments 
followed the general treatment model through Day 28 with some modifications. On Day 
27, a portion of the mice were given 30 µg CVF (Millipore Product #233552) to initiate 
complement depletion. These mice received the same dose of CVF every 3 days after the 
initial dose to maintain steady depletion throughout the post-infection challenge data 
collection period, according to the protocol established by Benhnia et. al (Supplemental 
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Figure 2-2)55. Following the ΔVn1203 (H5N1) infection challenge, percent survival and 
percent weight loss were recorded.  Data graphing and statistical analysis were completed 
using GraphPad Prism version 5.0. Survival experiments were analyzed using the 
Kaplan-Meier survival probability estimates. Weight loss comparisons were made using 
unpaired t tests. Quantitative differences between two samples were compared with the 
Mann-Whitney U test. P-value < 0.05 was considered significant. 
 
ELISA 
 An ELISA performed to assess the depletion of complement by CVF was 
performed using the Novateinbio C3a ELISA Kit (#NB-E20368). The ELISA was 
performed following the kit’s protocol.  
 
2.2: ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY 
EXPERIMENT 
2.2a: RELATIVE QUANTIFICATION OF Fc RECEPTOR BINDING 
 Fc receptor binding in vitro was relatively quantified in infected target cells using 
the Promega mFcγRIV (murine Fragmented, crystallized gamma receptor 4) Reporter 
Bioassay Kit (Promega M1201). The assay was performed according to the 
manufacturer’s protocol. Target cells were infected with A/HK/x31 or 
A/Vietnam/1203/4, and incubated with serum from a previous low-dose Rap treatment 
model, described above. Serum was heat treated to remove the impact of complement.  
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2.2b: ADCC SURVIVAL AND WEIGHT RATES 
Mice followed the general treatment model for PBS and Rap treatments 
(Supplemental Figure 2-1). Twelve hours prior to the challenge infection, a portion of 
the mice were given anti-NK depleting antibody (PK136) (Supplemental Figure 2-3).  
 
 Weight and survival data was monitored daily. Data graphing and statistical 
analysis was done using GraphPad Prism version 5.0. Survival experiments were 
analyzed using the Kaplan-Meier survival probability estimates. Weight loss comparisons 
were made using unpaired t tests. Quantitative differences between two samples were 
compared with the Mann-Whitney U test. P-value < 0.05 was considered significant. 
 
2.3: QUANTITATIVE POLYMERASE CHAIN REACTIONS (qPCRS) 
General B cell Purification 
Spleens were collected, mashed with screens, and spun down at 600 xg for 5 
minutes. After their red blood cells were lysed with 5 mL of 1X ACK Lysis Buffer for 2 
minutes, the leftover cells were topped with PBS + 2% serum and spun again. The cells 
were then resuspended in 5 mL PBS + 2% serum and counted in 0.04% Trypan Blue in 
PBS with a hemocytometer. After saving 1x106 cells for a purity check, a single-cell-
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suspension of lymphocytes at a concentration of 1x108 cells/mL was made in separation 
buffer. The cells were then transferred into 12x75 mm, 5 mL tubes at 2x108 cells/tube. B 
cells were negatively selected using the MagniSort Mouse B cell Enrichment Kit 
(eBioscience, 8804-6827).  
Setup 
After purification, the B cells were resuspended in RPMI at 4x106 cells/mL and 
plated in a 24 well plate at 2x106 cells/well. B cells were given 500 µL of just media, 
media with LPS (5 µg/mL) and IL-4 (10 ng/mL), or media with LPS (5 µg/mL), IL-4 (10 
ng/mL), and Rap (0.5 ng/mL) for 0, 24, or 48 hours of stimulation. At each time point, B 
cells were washed, centrifuged, and lysed in Buffer RLT with 2-Mercaptoethanol 
(1mL:10µL). To ensure complete mixing and lysis, the lysed B cells were vortexed and 
mixed thoroughly with a blunt needle. 
 
RNA Isolation 
RNA isolation was performed using a Qiagen RNeasy minikit according to the 
manufacturer’s protocol (#74104). 
 
RNA Quantification 
 Eluted RNA was quantified using a Nanodrop 8000 system. RNA quantities, 260 
nm/280 nm absorbance ratios, and 260 nm/230 nm absorbance ratios were recorded. 
Sample quality was determined by comparing recorded 260/280 values to the generally 
accepted RNA 260/280 ratio of 2. The unstimulated sample with the 260/280 value 
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furthest from this ratio was excluded from the study. Stimulated samples with 260/280 
ratios greater than 2.20 were also excluded.  
cDNA Synthesis 
 For each viable sample, volumes containing 750 ng of RNA were calculated and 
plated into a 96 well plate. Each sample well received 4 µL of 5X VILO Reaction Mix 
and 2 µL of 10X Superscript Enzyme Mix, each from a ThermoFisher Superscript VILO 
cDNA synthesis kit. Wells were then brought up to 20 µL with DEPC treated water. 
cDNA was synthesized in a Veriti 96 Well Fast Thermocycler in three stages: 10 minutes 
at 25°C, 60 minutes at 42°C, and 5 minutes at 85°C.  
 
qPCR Plate Preparation 
 Newly synthesized cDNA samples were transferred onto a 96 well plate and 
diluted with enough RNase-free water to bring the total volume of each well to 14 µL. 
The diluted cDNA samples were then aliquoted onto a new 96-well plate in 2.5 or 3 µL 
duplicates. Each sample and duplicate plate received 10 µL of qPCR master mix, 1 µL of 
primer for the gene of the transcription factor being tested, and enough RNase-free water 
to bring the total volume up to 20 µL. This process, duplicates included, was repeated on 
the bottom of the plate with a primer for GADPH as an endogenous control for the qPCR. 
Plates were covered with adhesive plastic and either run immediately after or stored 
covered on ice until they could be run.  
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qPCR and Statistical Analysis 
All qPCR’s were run on a standard protocol on a 7900HT qPCR instrument 
(Applied Biosystems). The data were analyzed using the RQ manager v1.2 software 
(Applied Biosystems) applying the ΔΔ CT method. The relative gene expression values 
obtained were plotted and statistical analysis carried out using GraphPad Prism. These 
differences were considered significant at the p=0.05 level.  
 
2.4: WESTERN BLOTS 
B cell Isolation and Purification 
B cells were isolated as above.   
 
Cell Stimulation and Plating 
The B cells were resuspended into 3 mL of RPMI media, and plated into 6 well 
plates at 50 x 106 cells/well. Cells were given 0.5ng/mL Rap, or media alone, for 2 hours 
followed by stimulation with LPS (5 µg/mL) and IL-4 (10 ng/mL) for 0, 1, 6, 24, and 48 
hours. At each time point, cells were pelleted and frozen for future analysis. The 48 hour 
Rap-treated B cells received an additional Rap spike of 1 ng/well after 24 hours to 
account for the half-life of rapamycin. 
 
BCA Protein Assay and Protein Quantification 
The stored B cells were put on ice and lysed with 45 µL ice cold RIPA buffer 
containing phosphatase and protease inhibitors for 30 minutes. The lysate was 
centrifuged at 20,000+ rpm for 5 minutes and the supernatant collected, and put on ice. 
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Protein was quantified via BCA Protein Assay. BCA Protein Assay was performed 
according to the manufacturers protocol (Pierce 23227). 
 
Membrane Preparation and Imaging 
Loading dye, sample buffer, and 30µg of lysate were combined and boiled prior 
to loading on the gel. The samples were then run on a Bis-Tris gel for 90 minutes at 150 
volts, and transferred to a nitrocellulose membrane at 250 milliamps (mAmps) for 1 hour. 
Membranes were blocked in 5% w/v BSA for 1 hour prior to overnight incubation with 
primary antibody (1:1000) at 4 °C. The membrane was washed and then incubated with 
Anti-rabbit IgG, HRP-linked secondary antibody (1:5000) in 5% w/v BSA in 1X TBST 1 
hour at room temperature. After incubation, the membrane was washed.  
Equal parts of Detection Reagent 1 and Detection Reagent 2 were mixed in a tube 
and vortexed to make developer. Developer was aliquoted onto a sheet protector, and a 
blot was placed down into it. Developer was aliquoted on top of the blot, the sheet 
protector was closed, and the blot was allowed to incubate for 4 minutes. The blots were 
placed in a new sheet protector with care taken to smooth out any bubbles before imaging 
in an Amersham Imager 600. After completing this process for phospho-antibody 
imaging, these blots were stripped , blocked, and probed for total protein following the 
above procedure. 
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2.5: LPS vs. αIgM STIMULATION FLOW CYTOMETRY 
B cell Isolation and Purification 
B cells were isolated as above.  
 
Cell Plating 
 Once the total number of B cells was counted, they were resuspended in RPMI 
media at 1x106 cells/mL. The cells were plated in a 96 plate well at 1x105 cells (100 
µL)/well in triplicates for each time point. The cells were pretreated as above. After 
incubating at 37°C for 2 hours, the plate was spun at 600xg for 5 minutes, and the 
supernatant removed. The 0 hour time point wells received 200µL of media alone and 
were subsequently transferred to pre-labeled Eppendorf tubes. Appropriate stimulation 
was then added to each remaining plate. Stimulation wells were plated in triplicates as 
follows:   
1. 200 µL of media with LPS (5ug/mL) + IL-4 (10ng/mL) at time points 1, 6, 24, 
and 48 hours 
2.  200 µL of media with LPS (5ug/mL) + IL-4 (10ng/mL) + Rap (0.5ng/mL) at time 
points 1, 6, 24, and 48 hours 
3. 200 µL of  media with anti-IgM (10ug/mL) + IL-4 (10ng/mL) at time points 1, 6, 
24, and 48 hours 
4. 200 µL of media with anti-IgM (10ug/mL) + IL-4 (10ng/mL) + Rap (0.5ng/mL) 
at time points 1, 6, 24, and 48 hours 
Cells were incubated at 37° C for indicated time points.  
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Cell Collection 
 At their collection times, the cells and their media were transferred to a pre-
labeled Eppendorf tube, and 200 µL of pre-heated fix buffer was added. Tubes were 
incubated in a water bath at 37°C for 10 minutes. After fixing, the tubes were centrifuged 
at 600xg for 5 minutes at 4° C. Supernatant was aspirated and replaced with 300 µL cold 
FACS Buffer. The 0 and 1 hour time point samples were left on ice until the 6 hour time 
point was harvested and fixed.  
Once all time points were fixed, samples were washed, and their supernatant 
aspirated. Perm buffer was added to each sample and transferred to a new 96 well plate 
that incubated on ice in the dark for 30 minutes. The plate was then spun down at 600xg 
for 5 minutes at 4°C. After all supernatant was removed, the plate was washed. This 
process was then repeated again with 100 µL of stain mix consisting of B220 to identify 
B cells, and either pS6 (Phospho-S6 Ribosomal Protein (Ser235/236) Antibody #2211) or 
p4E-BP1 (Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb #2855) as applicable. 
Single color controls were also stained in this way at this time. Fluorescently-tagged 
antibodies to 650, PE, FITC, all 3, and a blank sample were added and incubated on ice 
for 25 minutes. After incubation, the samples were washed and resuspended in 100uL of 
FACS buffer for analysis. After all samples had been collected, they were analyzed on a 
flow cytometer.  
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CHAPTER 3 
RESULTS 
3.1: THE ROLE OF COMPLEMENT IN HETEROSUBTYPIC IMMUNITY 
The complement system refers to a collection of serum proteins that work 
together to target and destroy pathogens in the blood. Through a cascade of stepwise 
cleavages, these proteins are converted to their active forms that induce pathogen death 
using a variety of pathways. Using the classical pathway of activation, the complement 
system can play a role in the elimination of virally-infected cells through cooperation 
with the adaptive immune system. As antibodies bind to viral epitopes, the formation of 
an antibody-antigen complex stimulates the exposure of a binding site for the first protein 
of the complement system, known as C1, on the antibody56. When C1 binds this 
antibody, the complement cascade begins. A few cleavages later, a cleaved C3 protein 
known as C3b can bind the Fc portions of the antibodies in the antigen-antibody 
complexes56. Phagocytes with C3b receptors can then engulf the entire infected cell and 
destroy it.  
We found that rapamycin enhanced heterosubtypic immunity by altering the 
antibodies generated during vaccination, such that these antibodies were more effective 
against influenza strains of different subtypes compared to antibodies generated in PBS 
control-treated mice. However, the antibodies generated in the rapamycin-treated mice 
were not neutralizing. In other words, these antibodies did not function by preventing the 
challenge virus from binding to host epithelial cells. Therefore, we investigated other 
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mechanisms by which these antibodies could enhance protection against multiple 
influenza subtypes. To determine whether the antibodies generated in the rapamycin-
treated mice utilized the complement system to provide heterosubtypic influenza 
protection, we depleted the complement system in vivo using cobra venom factor (CVF). 
CVF inhibits the complement system by forming an immune complex that functions as a 
C3/C5 convertase and resists normal methods of degradation57. This convertase 
continually cleaves 100% of C3 and C5 proteins to eventually deplete complement 
activity58.  
To examine the role of complement in vivo, we vaccinated the mice with HKx31 
(H3N2) virus as described previously, and waited 28 days to challenge with an H5N1 
virus. Half of the mice were treated with rapamycin and half with PBS. In addition, half 
of each PBS and Rap group was treated with CVF one day prior to infection, and every 
third day after that. To verify that complement was depleted, we performed an enzyme-
linked immunosorbent assay (ELISA) testing the serum levels of C3 in each group of 
mice. The lack of C3 in serum from CVF-treated mice confirmed depletion (Figure 3-1). 
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Interestingly, the depletion of complement increased mortality in both the PBS 
and the rapamycin-treated mice (Figure 3-2). However, the rapamycin-treated group still 
showed enhanced protection compared to the PBS control group, suggesting that 
rapamycin is enhancing survival through a mechanism independent of complement. Had 
rapamycin used the complement system to enhance protection, survival rates in 
complement-depleted PBS and RAP mice would have been similar. The 57% difference 
in survival between the two suggests that this was not the case (Figure 3-2).  
 
 
 
 
3.2: THE ROLE OF ANTIBODY-DEPENDENT CELL-MEDIATED 
CYTOTOXICITY (ADCC) IN HETEROSUBTYPIC IMMUNITY 
 Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) utilizes both the innate 
and adaptive immune systems to directly kill infected cells33. When a cell becomes 
infected with influenza, antigens of the specific influenza strain are presented on the 
surface of the infected cell, where they can be bound by an antibody whose variable 
region matches the antigen’s structure. Once the variable region is bound to its antigen, a 
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portion of the antibody’s constant region known as the Fc (Fragment, crystallizable) 
region can be bound by an Fc receptor (FcR) on natural killer (NK) cells. Upon binding, 
NK cells release cytotoxic molecules such as free radicals, perforins, and granzymes to 
kill the influenza-infected cell33.  
 To determine whether antibodies generated in the rapamycin-treated mice utilize 
ADCC to provide heterosubtypic influenza protection, we used an in vitro ADCC assay 
that measures the ability of antibodies to bind viral antigens and activate NK cells. Mice 
were vaccinated with the H3N2 strain and given either rapamycin or PBS. Serum was 
collected on day 28 following vaccination to measure the optimal antibody response. FcR 
binding specific for ADCC was measured in vitro using a specially-designed line of 
effector cells that express the primary murine ADCC receptor, mFcγRIV, on their 
surfaces, and a downstream luciferase gene. Binding to mFcγRIV by viral antibodies 
activates a signal transduction pathway that induces downstream activation of the 
luciferase gene via the calcium-mediated activation of the nuclear factor of activated T 
cells (NFAT) transcription factor. Luciferase activation produces a bioluminescence 
effect that can be relatively measured and quantified in relative light units (RLU). We 
measured the ability of the antibodies to mediate ADCC against the H3N2 strain they 
were vaccinated with, and the H5N1 strain they were challenged with. The antibodies 
that bind the H5N1 infected cells are cross-reactive antibodies. As a negative control, we 
measured binding of the antibodies to uninfected target cells. Additionally, we included 
serum from a naïve mouse (NMS) that has never been infected with influenza as another 
negative control to confirm that the activity that we observed was due to influenza-
specific antibodies. 
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As Figure 3-3 illustrates, serum from PBS and rapamycin-treated mice vaccinated 
with H3N2 contained more antibodies that mediated ADCC compared to naïve mice, 
demonstrating that our system was working. In addition, there was little antibody binding 
to uninfected targets. Interestingly, we detected no significant difference in FcR binding 
were detected between the serum of PBS and rapamycin-treated mice for either virus 
tested, although both groups showed elevated binding over normal mouse serum (NMS). 
While the antibodies of rapamycin-treated mice appear to bind mFcγRIV slightly more 
than the antibodies of PBS-treated mice, the difference is not significant, suggesting that 
rapamycin does not enhance protection by providing enhanced ADCC activity. However, 
these data do not indicate whether ADCC is required for the rapamycin-mediated 
protection or whether the antibodies in the rapamycin-treated mice are binding different 
viral epitopes compared to control-treated mice.  
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To test whether rapamycin-enhanced protection requires ADCC in vivo, we 
depleted NK cells in PBS and rapamycin-treated mice and compared their survival and 
weight loss rates to isotype-treated mice.  
 
 
 
 The near indistinguishability of the survival and weight-loss curves for isotype 
controls and NK-depleted mice indicates that ADCC activity is not required for 
rapamycin-mediated heterosubtypic protection (Figures 3-4, 3-5). Together, these results 
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with those of the FcR binding experiment suggest that rapamycin does not use ADCC as 
a means to enhance heterosubtypic immunity. 
 
3.3: THE ROLE OF LOW-DOSE RAPAMYCIN IN B CELL GENE EXPRESSION 
(qPCRs) 
 To investigate how low-dose rapamycin specifically alters the expression of 
certain downstream mTOR effectors in B cells, we analyzed the expression of genes 
known to be downstream of mTOR. qPCR quantifies gene expression by probing isolated 
cellular mRNA for specific gene sequences, and amplifying these sequences against a 
control gene to relatively quantify expression across different treatment conditions. The 
genes we tested encode transcription factors that regulate cellular energy production and 
antibody specificity. While it is known that mTOR is required for the expression of many 
genes, we did not know to what extent rapamycin was blocking these pathways given the 
low dose of rapamycin that we used in our experiments. These data will inform us which 
pathways may be important for generating optimal cross-reactive antibodies.  
 
3.3a: Pdk1 
The Pyruvate Dehydrogenase Kinase 1 (Pdk1) gene codes for the production of 
pyruvate dehydrogenase kinases, which serve as regulators of aerobic respiration59. A 
crucial step of aerobic respiration is the conversion of pyruvate to acetyl-CoA by a 
multienzyme complex known as pyruvate dehydrogenase (PDH). By phosphorylating 
PDH, pyruvate dehydrogenase kinases can inhibit its activity, which ultimately results in 
the reduction of cellular energy production.  In addition, previous studies indicated that 
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PDK1 regulates variable-diversity joining (V-DJ) recombination of both the heavy and 
light antibody chains in B cells60-61. V-DJ recombination promotes antibody specificity to 
combat the wide variety of antigens the immune system may encounter, and is necessary 
for B cells to generate antibodies specific for a particular antigen. In light of these 
functions and our previous data demonstrating that rapamycin inhibited B cell class-
switching, we hypothesized that rapamycin would lower Pdk1 expression to enhance 
energy for antibody production and reduce assembly of high affinity influenza-specific 
antibodies. 
 
 
 We found that B cells treated with rapamycin for 24 hours showed a decrease in 
Pdk1 mRNA relative to controls (Figure 3-6). However, this difference was not observed 
48 hours after stimulation. These data suggest that rapamycin temporarily decreases Pdk1 
expression, which may impact the ability of the B cells to undergo class switching.  
However, the differences were not statistically significant, so further studies would be 
necessary to confirm this finding.  
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3.3b: Slc2a1 
The Slc2a1 (Solute Carrier Family 2 Member 1) gene encodes GLUT1 (Glucose 
Transporter Protein Type 1), which functions as the primary glucose influx transporter 
protein in B cells and various other cell types62. It has been shown that GLUT1 
expression increases during B cell receptor stimulation to provide necessary fuel for 
maturation and proliferation63 Thus, in the context of heterosubtypic protection, we 
hypothesized that rapamycin would decrease GLUT1 expression to reduce proliferation 
of B cells, thereby reducing the high affinity strain specific influenza antibodies, allowing 
the antibodies specific for the more conserved regions to be more prevalent. 
 
 
To test whether the low dose of rapamycin impacted Slc21a1 expression, we 
stimulated B cells as previously described.  We found that Slc2a1 expression 
significantly decreased with Rap treatment at 24 hours compared to controls, which 
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validates our hypothesis that Rap decreases glucose uptake by GLUT1 in stimulated B 
cells. This trend suggests that glucose regulation plays an important role in restricting the 
development of strain-specific antibodies, though more tests would be necessary to 
confirm a definitive connection between the two. Interestingly, the trends at 24h and 48h 
appear to differ in that rapamycin increased Slc2a1 mRNA in 48h samples relative to 
controls. It should be noted, however, that this trend is consistent across every gene 
tested. Thus, it is not clear whether this difference is due to the stimulation conditions or 
if it is a true effect of rapamycin.  
 
3.3c: Xbp1 
The Xbp1 (X-box Binding Protein 1) gene encodes a bZIP (basic Leucine Zipper 
domain) protein that binds a promoter region of MHC II, and controls the differentiation 
of B cells into antibody-secreting plasma cells64,65. Given that this process is essential for 
plasma cell differentiation, we tested whether the low dose of rapamycin would impact 
Xbp1 expression66.  
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 To test this, we tested B cells as previously described. Although there was 
variability between our technical replicates, our data suggest that rapamycin decreased 
Xbp1 expression at 24 hours. By 48 hours Xbp1 expression was decreased in both groups.  
Therefore, these experiments will need to be repeated to determine if rapamycin does 
impact this pathway. If the trend at 24h holds up in future experiments, it might suggest 
that rapamycin restricts plasma cell differentiation to mitigate the response of strain-
specific influenza antibodies.  
 
3.3d: Irf4 
 Irf4 (Interferon Regulatory Factor 4) encodes a transcription factor that regulates 
interferons in response to viral infection67. In the context of heterosubtypic influenza 
protection, this gene is essential for germinal center formation in B cells, which is 
necessary for antibody class-switching and somatic hypermutation47,66,68. Based on the 
previous finding that rapamycin downregulates germinal center formation to partially 
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inhibit class-switching, we hypothesized that it might accomplish this through 
downregulation of Irf4 expression47. 
 
 We found that there were no significant differences in Irf4 expression in cells 
treated with rapamycin or control. Thus, the low dose of rapamycin does not appear to 
regulate Irf4 gene expression at these time points. Though this result is somewhat 
surprising, it may be rooted in Irf4’s dual role as a regulator of and requirement for 
plasma cell differentiation68. Since plasma cell differentiation is necessary for a robust 
antibody response, downregulation of this essential function through reduced Irf4 could 
antagonize rapamycin’s antibody-mediated protection. In addition, Irf4 expression levels 
may be different in response to influenza versus LPS and IL-4. 
 
3.3e: Hif1α 
Hif1α (Hypoxia-Inducible Factor 1 alpha subunit) encodes the alpha subunit of 
the transcription factor HIF1, which affects a variety of pathways to maintain 
homeostasis in response to hypoxia69. One of Hif1α’s most prominent functions in B cells 
38 
 
is glycolysis regulation. During development, Hif1α ensures the efficient use of glucose 
by the B cell to maintain energy requirements at various stages of maturation70. Without 
Hif1α, B cells do not develop properly. It has been shown that mTORC1 activation 
induces HIF1α activity. Thus, we wanted to know whether low-dose rapamycin would 
block Hif1α which may impact heterosubtypic immunity. Based on its requirement for 
proper B cell development, we hypothesized that some downregulation might occur.  
 
 
Despite a trend of lowered expression at 24h, Hif1α showed no significant 
differences in expression between stimulated control and rapamycin-treated B cells. 
Thus, we concluded that low-dose rapamycin does not significantly impact Hif1α gene 
expression.  
 
3.3f: c-Myc 
 The c-Myc gene encodes a multifunctional, nuclear phosphoprotein transcription 
factor that regulates the cell cycle, apoptosis, and cellular transformation through 
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targeting of specific genes71. One of c-Myc’s many functions in B cells is the ability to 
regulate germinal center formation. Through analyzing expression of downstream c-Myc 
effectors, studies demonstrated the necessity of c-Myc expression for proper functioning 
of germinal centers72. Thus, we wanted to determine whether low-dose rapamycin altered 
the expression of c-Myc to mediate the assembly of conserved cross-reactive antibodies 
and inhibit class-switching. Based on its role in germinal center regulation, we 
hypothesized that c-Myc expression would be downregulated by low-dose rapamycin.  
 
 
 Again, we found that there was a trend for decreased expression of c-Myc in the 
rapamycin-treated samples, but not a significant difference between the groups. If this 
trend was replicated in a repeat experiment with less variable data, it could indicate that 
rapamycin slightly decreases c-MYC expression, which may impact germinal center 
formation. Based on the current data alone, however, we must assume that low-dose 
rapamycin does not alter c-Myc expression to provide heterosubtypic influenza 
protection.  
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3.3g: Bach2:  
The Bach2 gene encodes a protein transcription factor that is required for class-
switch recombination, somatic hypermutation, and germinal center formation in B 
cells47,73,74. Based on these functions, we hypothesized that low-dose rapamycin would 
lower Bach2 expression to promote the reduction of these processes that we observed in 
previous experiments.  
 
 
 No significant differences were seen in Bach2 expression during qPCR analysis 
of splenic B cells. Interestingly, the trend of increased expression shown in 24h Rap 
samples contradicts our assertion that rapamycin would decrease Bach2 expression. If 
this trend persists in future experiments, it could mean that low-dose rapamycin uses 
Bach2 regulation to help maintain levels of germinal center formation appropriate for the 
production of its conserved neutralizing antibodies. However, the current data indicate 
that rapamycin does not regulate Bach2 expression to promote heterosubtypic protection.  
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Adapted from: 75. Laplante, M. & Sabatini, D. M. mTOR signaling at a glance. J. Cell Sci. 122, 3589–3594 (2009). 
  
 
 
3.4: THE ROLE OF LOW-DOSE RAPAMYCIN IN DOWNSTREAM 
PHOSPHOPROTEIN REGULATION  
 
One of mTOR’s best-characterized methods of cellular regulation is its ability to 
alter the phosphorylation state of downstream proteins upon activation. Given that 
rapamycin’s basic mechanism of action is the inhibition of mTOR, it follows that some 
portion of its therapeutic effects must rely on its curtailment of these alterations. To 
discover which proteins might play a role in our low dose of rapamycin’s provision of 
heterosubtypic influenza protection, we conducted western blots on a variety of known 
downstream mTORC1 proteins and compared their activation between control and 
rapamycin-treated B cells. 
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 The reduction in pS6 at earlier time points indicates that our low dose of 
rapamycin effectively decreases phosphorylation of S6 through its inhibition of mTOR 
(Figure 3-13). This result was validated using total S6 protein and β tubulin as loading 
controls to ensure differences in phosphorylation were not caused by disparities in protein 
quantity. Though it can be deduced from previous experiments, whose data are depicted 
above (Supplemental Figure 3-1), that this inhibition likely serves to reduce ribosome 
biogenesis, and thereby protein synthesis, it is unclear how these reductions might assist 
in the provision of heterosubtypic influenza protection.   
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 In response to stimulation, expression of p4E-BP1 steadily increased in both 
rapamycin-treated and control B cells, but was not impacted by the low dose of 
rapamycin (Figure 3-15). This result was validated by the use of total 4E-BP1 and 
GAPDH as loading controls to ensure comparable protein distribution across wells. 
Based on the data, and known functions of p4E-BP1, we conclude that low-dose 
rapamycin does not alter protein synthesis through regulation of cap-dependent 
translocation through this pathway.  
3.5: LPS vs. anti-IgM STIMULATION COMPARISON 
 To determine if rapamycin may impact the mTOR pathway differently in 
response to other stimuli, we also analyzed the activation of S6 and 4EBP1 by flow 
cytometry following stimulation with anti-IgM and LPS.  
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 Although the stimuli do differ kinetically, the significant differences in 
phosphoprotein expressions between rapamycin-treated and control media cells are 
preserved across stimuli. In both cases, anti-IgM stimulated cells show an expression 
peak at 6 hours, before steadily decreasing as time goes on, while LPS-stimulated cells 
are more steadily expressed throughout stimulation. These trends indicate anti-IgM 
stimulation as a faster, more specific B cell stimulus than LPS. Since significant 
differences are consistent, however, the difference in these trends would not affect overall 
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expression data and interpretation. Thus, this experiment served to validate our previous 
results.  
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CHAPTER 4 
 DISCUSSION 
4.1: THE FUNCTIONALITY OF RAPAMYCIN-MEDIATED 
HETEROSUBTYPIC INFLUENZA PROTECTION 
 A low dose of rapamycin (75 µg/kg) enhances protection against multiple 
subtypes of influenza when given during vaccination. However, the mechanisms of 
action remain unclear. Previous experiments showed that rapamycin promoted the 
generation of antibodies that did not neutralize influenza infection in vitro. Therefore, we 
tested other mechanisms by which non-neutralizing antibodies protect in order to further 
characterize the rapamycin-mediated response of these antibodies to influenza infection. 
One of the most prominent protective mechanisms of non-neutralizing antibodies is 
complement-mediated phagocytosis. This mechanism employs non-neutralizing 
antibodies to form antibody-antigen complexes in response to viral infection. These 
complexes expose antibody receptors for serum complement proteins to bind for the 
purpose of attracting macrophages with complement receptors that engulf and destroy 
virally-infected cells. We found that antibodies generated in the presence of rapamycin 
did not require activity of the complement system to provide protection. Depletion of 
complement in vivo did not significantly alter rapamycin-mediated protection following a 
lethal heterosubtypic infection. Rapamycin increased survival rates by 44% compared to 
PBS control mice when complement was present, and 57% in complement-depleted 
mice. These data suggest that low-dose rapamycin does not require complement to 
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enhance protection. If the complement system assisted rapamycin in providing 
heterosubtypic immunity, its depletion should have decreased rapamycin-mediated 
survival rates relative to controls. However, the opposite trend occurred here. While 
complement depletion did not significantly alter relative mortalities between control and 
CVF treatment groups, it did increase overall mortality in both PBS and rapamycin-
treated mice, suggesting that the complement system plays an important role in the 
defense against influenza protection independent of rapamycin treatment.  
  Additionally, we found that antibodies generated in the presence of rapamycin did 
not exhibit increased levels of ADCC compared to antibodies generated in control mice. 
We tested antibodies from mice vaccinated with H3N2 and treated with rapamycin or a 
PBS control in an in vitro ADCC assay, and did not observe a difference in ADCC 
between the groups. These data do not rule out that ADCC is required for the antibodies 
to mediate protection, but there is not increased ADCC compared to antibodies in control 
mice. To further address whether ADCC was required, we depleted NK cells in vivo prior 
to challenge with the lethal heterosubtypic strain, and observed that NK cell depletion did 
not impact survival or weight loss rates in vivo, suggesting that ADCC is not required for 
rapamycin-mediated protection. While FcR binding did not significantly differ between 
antibodies of rapamycin-treated mice and antibodies of PBS-treated mice, both treatment 
groups did experience noticeable increases in binding after vaccination. These increases 
suggest that ADCC activity is present during the immune system’s fight against influenza 
infection, and could play an important role in viral clearance of influenza, but it is not 
increased by rapamycin. Interestingly, the antibodies of rapamycin-treated mice appeared 
to bind FcRIV slightly more than the antibodies of PBS-treated mice. However, this 
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trend’s extension to uninfected cells implies that the increases in binding may not be 
influenza-specific. Together, our data showed that ADCC activity was not increased in 
the serum of rapamycin-treated mice compared to control-treated mice after vaccination, 
and NK cells were not required for the rapamycin-mediated protection, suggesting that 
the antibodies generated in the presence of rapamycin do not utilize ADCC to mediate 
protection. 
 Given that ADCC and complement were not required for rapamycin to enhance 
heterosubtypic protection, it stands that another facet of the immune system must be 
employed to achieve heterosubtypic immunity. The most likely remaining mechanism of 
action for these antibodies is FcR-mediated phagocytosis. A previous study with an 
infection model similar to our own found that this mechanism was necessary for 
heterosubtypic influenza protection in vivo, but not in vitro53. This assertion would fit 
with our data on FcR binding since the lack of significant differences in binding between 
PBS and rapamycin treated mice was found in vitro. In the previous study, loss of 
protection was found with inhibition of Fcγ receptor action and depletion of alveolar 
macrophages through intranasal administration of clodronate-loaded liposomes53. Thus, 
this study provides a new, interesting lead in the hunt for the mechanism by which 
antibodies generated in the presence of rapamycin enhance protection against multiple 
subtypes of influenza.  
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4.2: REGULATION OF DOWNSTREAM mTOR EFFECTORS BY LOW-DOSE 
RAPAMYCIN 
 In order to understand how a low dose of rapamycin enhances heterosubtypic 
immunity, we analyzed its impact on genes known to be downstream of mTOR. Through 
qPCR analysis, we found that a low dose of rapamycin reduced expression of Slc2a1 in B 
cells following in vitro stimulation. The downregulation of Slc2a1 reduces cellular 
glucose uptake by partially inhibiting transcription of primary glucose transporter protein 
GLUT1. While a definitive relationship between glucose regulation and heterosubtypic 
protection has not yet been established, its existence seems likely based on previous 
research. Studies showed that B cells increase glucose uptake via GLUT1 in the pro-B 
cell stage, and in response to anti-IgM stimulation70,63. These findings suggest that B cells 
have higher energy requirements at these times.  
Both the pro-B cell stage and IgM stimulation are critical for generating specific 
antibodies. During the pro-B cell stage of development, antibody heavy chains undergo 
V-DJ recombinations that alter the specificity of the antibody heavy chain, which impacts 
what antigens the antibody binds, and is required for further development and 
proliferation of B cells35. Thus, by downregulating Slc2a1 expression in pro-B cells, a 
low dose of rapamycin may restrict glucose intake enough to reduce energy levels 
beneath the threshold required to maintain these recombinations. In this way, rapamycin 
could inhibit the production of new B cells that have strain-specific antibodies. The 
reduction of Slc2a1 expression by rapamycin may also limit antibody specificities after 
V-DJ recombination by inhibiting germinal center activity. Since glucose intake increases 
during germinal center formation, which occurs in response to antibody stimulation, 
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limiting glucose intake would limit energy for class switch recombination and somatic 
hypermutation. Both class switch recombination and somatic hypermutation in the 
germinal centers are the main mechanisms by which high affinity antibodies that are 
specific for the variable regions of influenza HA develop. In the germinal centers, the 
antibodies with the highest affinity for the pathogen are selected to develop, and 
outcompete other antibodies of lower affinities33. For influenza, the highest affinity 
antibodies typically bind to the globular head of the HA protein, which in turn, causes the 
globular head to be the most variable region of the virus. We hypothesize that a low dose 
of rapamycin partially blocks the germinal center formation and generation of the high 
affinity antibodies, which allows the lower affinity antibodies to the conserved portions 
of the virus to be more prevalent. It is possible that reduction of Slc2a1 may mediate this 
block in germinal centers, but, further tests would have to be conducted to validate this 
hypothesis.  
Interestingly, the trend of rapamycin-mediated Slc2a1 regulation seemed to 
switch from downregulation at 24 hours to upregulation at 48 hours. Although the trend 
of upregulation is significant, its validity is questionable for two reasons. First, the trend 
of increased genetic expression in rapamycin-treated cells relative to controls was present 
for every gene tested at 48 hours. While it is possible that rapamycin actually increased 
expression for all 7 genes tested at 48 hours, it is more probable that this trend stems from 
the delayed kinetics of LPS stimulation. As shown in Figures 3-16 and 3-17, LPS 
stimulates B cells at slower rate than anti-IgM. As a result, gene expression in LPS and 
rapamycin-treated cells may appear higher at 48 hours because it is delayed compared to 
IgM stimulation. Thus, a repeat of these experiments with anti-IgM stimulation would be 
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valuable to confirm conclusions and nonsignificant trends in expression. Additionally, the 
margin of difference in relative Slc2a1 expression between stimulated controls and 
stimulated rapamycin-treated cells drops 2.5 percentage points from the 24 hours to 48 
hours. Thus, the significance of the difference at 48 hours is diminished, casting further 
doubt on its validity. 
Another potential flaw in the qPCR results was large RQ (relative quantity of 
gene expression) variability within treatment groups. The most glaring instance of this 
trend occurred during Xbp1 analysis (Figure 3-9). While most RQ values range between 
0 and 3, Xbp1 showed RQ values upward of 500 in both stimulated controls and 
rapamycin-treated cells at 24 hours. After excluding these values, a 24 hour stimulated 
control sample with an RQ of approximately 64 remained, which accounts for its 
exaggerated expression and error bar relative to other Xbp1 treatment groups. Similar 
variabilities occurred to lesser extents with other genes. These variabilities may have 
resulted from technical errors and deficiencies in eluted RNA quantity. For this reason, 
and the potential effects of LPS stimulation, these experiments will need to be repeated to 
confirm any nonsignificant trends seen in our data.  
We also found that rapamycin reduced pS6 expression in vitro via western blot 
analysis. During activation, mTORC1 indirectly phosphorylates pS6 to promote ribosome 
biogenesis for protein synthesis75. Thus, a low dose of rapamycin inhibited mTOR 
sufficiently to prevent phosphorylation of pS6. Use of total protein controls S6 and β 
tubulin confirmed that differences in expression were not due to sample loading errors. 
While it is unclear how rapamycin-mediated inhibition of ribosome biogenesis, and 
subsequent protein synthesis, might directly promote heterosubtypic influenza protection, 
52 
 
it is interesting to note that this reduction only occurs at early time points of 0, 1, and 6 
hours. Since we controlled for the half-life of rapamycin in 48 hour samples by providing 
an extra dose of rapamycin (1 ng/well) and did not observe any further alteration of pS6 
expression, these trends may indicate that mTOR exhibits a decreased sensitivity to 
rapamycin after only initial stimulation in vitro.  
Overall, our data indicate that low-dose rapamycin does not require the activity of 
the complement system or ADCC to provide optimal heterosubtypic immunity, but may 
promote heterosubtypic protection by reducing the expression of Slc2a1 and pS6. 
Although the protective mechanisms of rapamycin-mediated non-neutralizing antibodies 
remain unclear, the elimination of the complement system and ADCC from the pool of 
suspects leaves us one step closer to finding the true mechanism by which these 
antibodies function. The reduction of Slc2a1 expression by low-dose rapamycin confirms 
that rapamycin influences genetic regulation, although the specific mechanisms remains 
unclear. Finally, the inhibition of pS6 phosphorylation, coupled with the lack of activity 
on p4E-BP1, indicates the partial block of mTOR by the low dose of rapamycin is 
specific in its alterations of downstream effectors. Understanding how rapamycin alters 
the immune system to enhance immunity to multiple subtypes of influenza will aid in 
developing a universal influenza vaccine, which could potentially save millions of lives 
in the event of a deadly pandemic. 
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